TLRY Stock Overview
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TLRY from our risk checks.
Tilray Brands, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.66 |
| 52 Week High | US$3.37 |
| 52 Week Low | US$1.50 |
| Beta | 2.18 |
| 11 Month Change | -4.05% |
| 3 Month Change | -7.26% |
| 1 Year Change | -44.30% |
| 33 Year Change | -87.03% |
| 5 Year Change | n/a |
| Change since IPO | -89.69% |
Recent News & Updates
Recent updates
Tilray Brands (NASDAQ:TLRY) Is Making Moderate Use Of Debt
Sep 05
Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jul 31Tilray Shows Some Nice Improvement In Q4
Jul 30Tilray Should Be Cut From Your Portfolio
Jul 14Why Bears Think Tilray Brands Will Continue To Dip
May 29Tilray Takes A Step Forward
May 21An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 34% Undervalued
May 01Tilray Could Break Down
Apr 07Tilray Brands, Inc.'s (NASDAQ:TLRY) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 27Tilray: Big Opportunities Ahead In Germany And Alcohol Segment
Mar 12Tilray Brands (NASDAQ:TLRY) Is Carrying A Fair Bit Of Debt
Jan 25Tilray Remains Stuck In Neutral
Jan 10Tilray Brands, Inc.'s (NASDAQ:TLRY) Price Is Right But Growth Is Lacking
Dec 19Industry Analysts Just Upgraded Their Tilray Brands, Inc. (NASDAQ:TLRY) Revenue Forecasts By 13%
Oct 10Analysts Are Upgrading Tilray Brands, Inc. (NASDAQ:TLRY) After Its Latest Results
Oct 06Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 18Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues
Apr 17Shareholder Returns
| TLRY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.4% | 0.1% | -1.4% |
| 1Y | -44.3% | 21.4% | 21.1% |
Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 21.4% over the past year.
Return vs Market: TLRY underperformed the US Market which returned 21.1% over the past year.
Price Volatility
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TLRY has not had significant price volatility in the past 3 months.
Volatility Over Time: TLRY's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2,650 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.
Tilray Brands, Inc. Fundamentals Summary
| TLRY fundamental statistics | |
|---|---|
| Market cap | US$1.08b |
| Earnings (TTM) | -US$244.98m |
| Revenue (TTM) | US$788.94m |
1.4x
P/S Ratio-4.4x
P/E RatioIs TLRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLRY income statement (TTM) | |
|---|---|
| Revenue | US$788.94m |
| Cost of Revenue | US$553.36m |
| Gross Profit | US$235.58m |
| Other Expenses | US$480.56m |
| Earnings | -US$244.98m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 29.86% |
| Net Profit Margin | -31.05% |
| Debt/Equity Ratio | 9.3% |
How did TLRY perform over the long term?
See historical performance and comparison